Recruiting
Phase 1

Nivolumab & ASTX727

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05272384

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma

Recurrent Hodgkin Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma

Refractory Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Decitabine and Cedazuridine

Nivolumab

Positron Emission Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-14.